TALARIS THERAPEU(TALS) - 2024 Q4 - Annual Results

Exhibit 99.1 Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights – Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the second quarter of 2025 – – Cardiovascular Scientific Advisory Board strengthened with recent appointments of Drs. Deepak L. Bhatt, Dipender Gill, Paul M. Ridker, and Tabassome Simon – – Cash, cash ...